

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/683,815
	Filing Date	October 9, 2003
	First Named Inventor	Arnon ROSENTHAL
	Art Unit	1649
	Examiner Name	S. Turner
Total Number of Pages in This Submission	10+47 References	Attorney Docket Number 514712001500

ENCLOSURES (Check all that apply)

☐ Fee Transmittal Form ☐ Fee Attached ☐ Amendment/Reply ☐ After Final ☐ Affidavits/declaration(s) ☐ Extension of Time Request ☐ Express Abandonment Request ☒ Information Disclosure Statement (3 pages) ☐ Certified Copy of Priority Document(s) ☐ Reply to Missing Parts/ Incomplete Application ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53	☐ Drawing(s) ☐ Licensing-related Papers ☐ Petition ☐ Petition to Convert to a Provisional Application ☐ Power of Attorney, Revocation Change of Correspondence Address ☐ Terminal Disclaimer ☐ Request for Refund ☐ CD, Number of CD(s) _____ ☐ Landscape Table on CD	☐ After Allowance Communication to TC ☐ Appeal Communication to Board of Appeals and Interferences ☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) ☐ Proprietary Information ☐ Status Letter ☒ Other Enclosure(s) (please Identify below): PTO/SB/08a/b + copy (6 pages) References (47) Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Jie Zhou		
Date	September 19, 2005	Reg. No.	52,395

I hereby certify that this correspondence is being hand delivered to: U.S. Patent and Trademark Office, Customer Service Window, MS Amendment, Randolph Building, 401 Dulany Street, Alexandria, Virginia 22314, on the date shown below.

Dated: September 27, 2005

Signature:

(Shari Hall-White)



CERTIFICATE OF MAILING BY "HAND DELIVERY"

I hereby certify that this correspondence is being hand delivered to: U.S. Patent and Trademark Office, Customer Service Window, MS Amendment, Randolph Building, 401 Dulany Street, Alexandria, VA 22314, on the date shown below.

Date: 9/27/05

Signature: Sheri-Hall White

Sheri-Hall White

Patent

Docket No. 514712001500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Arnon ROSENTHAL et al.

Serial No.: 10/683,815

Filing Date: October 9, 2003

For: METHODS OF TREATING
ALZHEIMER'S DISEASE USING
ANTIBODIES DIRECTED AGAINST
AMYLOID BETA PEPTIDE AND
COMPOSITIONS THEREOF

Examiner: S. Turner

Group Art Unit: 1649

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, Virginia 22314

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.


The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 514712001500.

Dated: September 19, 2005

Respectfully submitted,

By 
Jie Zhou
Registration No.: 52,395
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-5922



ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/683,815
				Filing Date	October 9, 2003
				First Named Inventor	Arnon ROSENTHAL
				Art Unit	1649
				Examiner Name	S. Turner
Sheet	1	of	3	Attorney Docket Number	514712001500

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1.	US-2002/0028473-A1	03-07-2002	Averback	
	2.	US-2002/0136718-A1	09-26-2002	Raso	
	3.	US-2002/0197258-A1	12-26-2002	Ghanbari et al.	
	4.	US-2002/0197831-A1	12-26-2002	Todd et al.	
	5.	US-2003/0068316-A1	04-10-2003	Klein et al.	
	6.	US-2003/0073655-A1	04-17-2003	Chain	
	7.	US-2003/0108551-A1	06-12-2003	Nicolau et al.	
	8.	US-2003/0147882-A1	08-07-2003	Solomon et al.	
	9.	US-2003/0235872-A1	12-25-2003	Small et al.	
	10.	US-2003/0235897-A1	12-25-2003	Raso	
	11.	US-2004/0081657-A1	04-29-2004	Schenk	
	12.	US-2004/0197831-A1	10-07-2004	Weksler et al.	
	13.	US-2004/0219146-A1	11-04-2004	Schenk	
	14.	US-2004/0241164-A1	12-02-2004	Bales et al.	
	15.	US-2004/0265308-A1	12-30-2004	Schenk	
	16.	US-2005/0019328-A1	01-27-2005	Schenk	
	17.	US-2005/0019330-A1	01-27-2005	Schenk	
	18.	US-2005/0048049-A1	03-03-2005	Schenk	
	19.	US-2005/0129691-A1	06-16-2005	Gerlai	
	20.	US-5,231,170-A	07-27-1993	Averback	
	21.	US-5,688,651-A	11-18-1997	Solomon	
	22.	US-6,582,945-B1	06-24-2003	Raso	
	23.	US-6,743,427-B1	06-01-2004	Schenk	
	24.	US-6,750,324-B1	06-15-2004	Schenk et al.	
	25.	US-6,761,888-B1	07-13-2004	Schenk	
	26.	US-6,787,523-B1	09-07-2004	Schenk	
	27.	US-6,787,637-B1	09-07-2004	Schenk	
	28.	US-6,815,175-B2	11-09-2004	Weksler et al.	
	29.	US-6,872,554-B2	03-29-2005	Raso	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	30.	WO-90/09789-A2	09-07-1990	Averback		
	31.	WO-90/12870-A1	11-01-1990	Research Foundation for Mental Hygiene, Inc.		
	32.	WO-95/16917-A1	06-22-1995	Averback		
	33.	WO-96/15799-A1	05-30-1996	Rutgers, The State University of New Jersey		
	34.	WO-96/18900-A1	06-20-1996	Ramot-Univ. Authority For Applied Research and Industrial Development Ltd.		
	35.	WO-98/33815-A1	08-06-1998	Acumen Pharmaceuticals, Inc.		
	36.	WO-00/72880-A2, A3	12-07-2000	Neuralab Limited		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa-996225

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/683,815
				Filing Date	October 9, 2003
				First Named Inventor	Arnon ROSENTHAL
				Art Unit	1649
				Examiner Name	S. Turner
Sheet	2	of	3	Attorney Docket Number	514712001500

37.	WO-00/77178-A1	12-21-2000	Boston Biomedical Research Institute		
38.	WO-01/10900-A2, A3	02-15-2001	University of Southern California et al.		
39.	WO-03/000714-A2, A3	01-03-2003	Panacea Pharmaceuticals, Inc.		
40.	WO-03/015691-A2, A3	02-27-2003	Eli Lilly and Company		
41.	WO-03/016467-A2, A3	02-27-2003	Eli Lilly and Company		
42.	WO-03/039467-A2, A3	05-15-2003	Diagenics International Corporation		
43.	WO-03/051374-A2, A3	06-26-2003	New York State Office of Mental Health		
44.	WO-03/074081-A1	09-12-2003	Mindset Biopharmaceuticals USA Inc.		
45.	WO-03/090772-A1	11-06-2003	Eli Lilly and Company		
46.	WO-03/104437-A2, A3	12-18-2003	Northwestern University et al.		
47.	WO-2004/001426-A2, A3	12-31-2003	Axonyx, Inc.		
48.	WO-2004/024090-A2	03-25-2004	The Regents of the University of California		
49.	WO-2004/024770-A1	03-25-2004	Universidad de Zaragoza		√
50.	WO-2004/029630-A1	04-08-2004	Janssen Pharmaceutica N.V.		
51.	WO-2004/032868-A2	04-22-2004	Rinat Neuroscience Corp.		
52.	WO-2004/056318-A2	07-08-2004	New York University		
53.	WO-2004/067561-A1	08-12-2004	Abbott GMBH & Co. KG	Translation of Abstract Only	
54.	WO-2004/076677-A2, A3	09-10-2004	Institute for Research in Biomedicine		
55.	WO-2004/098631-A1	11-18-2004	Universidad de Zaragoza		√
56.	WO-2005/011599-A2	02-10-2005	Northwestern University		
57.	WO-2005/018424-A2	03-03-2005	Research Foundation for Mental Hygiene, Inc.		
58.	WO-2005/025516-A2	03-24-2005	The Regents of the University of California		
59.	WO-2005/025616-A1	03-24-2005	Takeda Pharmaceutical Company Limited		√
60.	WO-2005/028511-A2	03-31-2005	Centocor, Inc.		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	61.	Akiyama, H. et al. (February 2004). "Specificity of Mechanisms for Plaque Removal after Aβ Immunotherapy for Alzheimer Disease," <i>Nature Medicine</i> 10(2):117-119.		
	62.	Bard, F. et al. (February 18, 2003). "Epitope and Isotype Specificities of Antibodies to β-Amyloid Peptide for Protection Against Alzheimer's Disease-Like Neuropathology," <i>Proc. Natl. Acad. Sci. USA</i> 100(4):2023-2028.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/683,815
				Filing Date	October 9, 2003
				First Named Inventor	Arnon ROSENTHAL
				Art Unit	1649
				Examiner Name	S. Turner
Sheet	3	of	3	Attorney Docket Number	514712001500

63.	Bussi�re, T. et al. (September 2004). "Animal Model: Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A� Immunotherapy on Their Clearance," <i>American Journal of Pathology</i> 165(3):987-995.	
64.	Friend, P.J. et al. (December 15, 1999). "Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection," <i>Transplantation</i> 68(11):1632-1637.	
65.	Gaskin, F. et al. (April 1993). "Human Antibodies Reactive with �-Amyloid Protein in Alzheimer's Disease," <i>J. Exp. Med.</i> 177:1181-1186.	
66.	Goding, J.W. (1983). "Production of Monoclonal Antibodies" Chapter 3 In <i>Monoclonal Antibodies: Principles and Practice</i> Academic Press, Inc.:New York, NY, pgs. 56-97.	
67.	Gregory, G.C. et al. (2005). "What is the Dominant A� Species in Human Brain Tissue?" <i>Neurotoxicity Research</i> 7(1,2):29-41.	
68.	Klyubin, I. et al. (May 2005). "Amyloid � Protein Immunotherapy Neutralizes A� Oligomers That Disrupt Synaptic Plasticity <i>in vivo</i> ," <i>Nature Medicine</i> 11(5):556-561.	
69.	Price, D.L. et al. (July 1993). "Alzheimer Disease and the Prion Disorders Amyloid �-Protein and Prion Protein Amyloidoses," <i>Proc. Natl. Acad. Sci. USA</i> 90:6381-6384.	
70.	Saido, T.C. et al. (May 27, 1994). "Spatial Resolution on the Primary �-Amyloidogenic Process Induced in Postischemic Hippocampus," <i>J. Bio. Chem.</i> 269(21):15253-15257.	
71.	Spillantini, M.G. et al. (May 1990). "Different Configurational States of �-Amyloid and Their Distributions Relative to Plaques and Tangles in Alzheimer Disease," <i>Proc. Natl. Acad. Sci. USA</i> 87:3947-3951.	
72.	Sugarman, M.C. et al. (April 30, 2002). "Inclusion Body Myositis-Like Phenotype Induced by Transgenic Overexpression of �APP in Skeletal Muscle," <i>Proc. Natl. Acad. Sci. USA</i> 99(9):6334-6339.	
73.	Vehmas, A.K. et al. (2001). "�-Amyloid Peptide Vaccination Results in Marked Changes in Serum and Brain A� Levels in APPsw/PS1�E9 Mice, as Detected by SELDI-TOF-Based ProteinChip� Technology," <i>DNA and Cell Biology</i> 20(11):713-721.	
74.	Walker, L.C. et al. (July 1994). "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <i>Journal of Neuropathology and Experimental Neurology</i> 53(4):377-383.	
75.	Wilcock, D.M. et al. (2004). "Passive Immunotherapy Against A� in Aged APP-Transgenic Mice Reverses Cognitive Deficits and Depletes Parenchymal Amyloid Deposits in Spite of Increased Vascular Amyloid and Microhemorrhage," <i>Journal of Neuroinflammation</i> 1:1-11.	
76.	Wilcock, D.M. et al. (July 7, 2004). "Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition," <i>The Journal of Neuroscience</i> 24(27):6144-6151.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa- 996225